# MT-304

Source: https://onco.cc/drugs/mt-304/  
OnCo record `mt-304` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MT-304 is an experimental in vivo CAR therapy from CREATE Medicines, in phase 1 trials for solid tumours that carry HER2.

## Summary

MT-304 is an in vivo CAR therapy: mRNA in lipid nanoparticles that programmes NK and myeloid cells from CREATE Medicines. Messenger RNA in lipid nanoparticles makes the patient's own NK cells and myeloid cells carry a chimeric antigen receptor against HER2. The phase 1 study NCT07334119 tests it alone and with nivolumab in HER2-expressing solid tumours. Whether it works in people has not been established.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Code: MT-304
- Modality: In vivo CAR therapy: mRNA in lipid nanoparticles that programmes NK and myeloid cells
- Mechanism: Messenger RNA in lipid nanoparticles makes the patient's own NK cells and myeloid cells carry a chimeric antigen receptor against HER2.

## Sources

- CREATE Medicines: https://createmedicines.com/
- ClinicalTrials.gov NCT07334119: https://clinicaltrials.gov/study/NCT07334119

## Connected records

- targets: [HER2](https://onco.cc/targets/her2/)
- companies: [CREATE Medicines](https://onco.cc/companies/create-medicines/)
- trials: [Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors](https://onco.cc/trials/nct07334119/)

---
JSON: https://onco.cc/api/v1/entities/mt-304.json